By owning full rights to the drug, Biogen will be able to more easily streamline its marketing with other MS drugs, including Avonex and Tecfidera, formerly known as BG-12, a pill that is awaiting FDA approval.
FORBES: In Wise Move, Biogen Spends $3.25 Billion For Rest Of Tysabri. Now What Happens To Elan?